Download CareClinic today and experience the difference that comprehensive tracking can make in your GLP-1 treatment journey
Lpez-Cano C, Ciudin A, Snchez E, Tinahones FJ, Barb F, Dalmases M, et al
Epidemiology of Type 2 Diabetes Global Burden of Disease and Forecasted Trends
Among the key observed effects, several stand out as particularly relevant to the Alzheimer's disease framework
Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)
